BOSTON SCIENTIFIC NEUROMODULATION VERCISE GENUS; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN SYMPTOMS
|
Back to Search Results |
|
Model Number DB-1216 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Depression (2361); Convulsion/Seizure (4406)
|
Event Date 12/08/2022 |
Event Type
Injury
|
Event Description
|
It was reported that the clinical study patient experienced an epileptic seizure, which was assessed as being mild in severity.The event was resolved.The physician assessed the event as having a possible relationship to the procedure, but the relationship to the device was reported as not related.
|
|
Manufacturer Narrative
|
Additional suspect medical device components involved in the event: product family: dbs-linear leads, upn: m365db2202300, model: db-2202-30, serial: (b)(4), batch: 7076176.Product family: dbs-linear leads, upn: m365db2202300, model: db-2202-30, serial: (b)(4), batch: 7076980.
|
|
Manufacturer Narrative
|
Additional suspect medical device components involved in the event: product family: dbs-linear leads, upn: m365db2202300, model: db-2202-30, serial: (b)(6), batch: (b)(6).Product family: dbs-linear leads, upn: m365db2202300, model: db-2202-30, serial: (b)(6), batch: (b)(6).
|
|
Event Description
|
It was reported that the clinical study patient experienced an epileptic seizure, which was assessed as being mild in severity.The event was resolved.The physician assessed the event as having a possible relationship to the procedure, but the relationship to the device was reported as not related.Additional information was received that complications such as a bleed or fresh ischemia, cerebrospinal fluid circulation disorder, and signs of herniation were excluded through a cranial computed tomography (ct) scan and chest x-ray.The deep brain stimulation (dbs) system was also in regular position.An additional therapy with levetiracetam was initiated to treat the patient.No new abnormalities in the sense of an epileptic event were recorded over the short-term course of inpatient treatment.The lab tests revealed a valproic acid level below the therapeutic limit, for which reason the patients dose of medication was increased.The physician deescalated levetiracetam with the goal of establishing monotherapy again over time.Due to the patients reported depressed mood due to the disease and the mood-stabilizing effect of valproic acid, the physician did not recommend discontinuing or substituting the patients medication at this time.
|
|
Search Alerts/Recalls
|
|
|